Agoracom Blog Home

Posts Tagged ‘CBD’

VIDEO – Hollister $HOLL.ca $HSTRF Reports Record Q3 Revenues With $12.5M From 360+ Dispensaries In California and Arizona $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 4:23 PM on Monday, November 9th, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1

Hollister Biosciences (HOLL:CSE) is a multi-state operator with multiple, high-quality products that are now carried in 280 of California’s 600 dispensaries, where it also claims California’s #1 hash infused pre-roll “HashBone” … and if that is all they had you would have the makings of a great small cap cannabis company. 

But there is more …. way more. 

Venom Extracts is their 100% owned subsidiary that is absolutely dominating the state of Arizona.  More than just lip service:

  • Venom just surpassed $30,000,000 (MILLION) in revenue YEAR TO DATE
  • Venom Extracts is one of Arizona’s premier extract brands 
  • One of the state’s largest producers of medical cannabis distillate and related products
  • The products are award winning
  • ….. And it is run by the absolute coolest guy in small cap Cannabis – Jake Cohen  

THE NUMBERS SAY IT ALL 

1.  RECORD Q3 REVENUE          $12.5M 

2.  CRAZY REVENUE GROWTH    5,200%

3.  RECORD EBITDA                 $1.265M (vs a loss of $362,000) In case you’re wondering if this was a fluke quarter, this is what Q2 looked like: 

  • RECORD REVENUE of $US 8.47M, compared to $200,000 last year and representing an increase of 4,170%
  • NET INCOME of $300,000, compared to a loss of $2.1M, representing a turnaround of $2.4M over last year 

HOLLISTER HEADED TOWARDS $50,000,000 REVENUE? 

If you’re paying attention, HOLL is achieving enormous growth both year over year and sequentially.  If we extrapolate the latest Q3 numbers, Hollister is on a $50,000,000 annualized revenue run rate assuming no further growth. 

But there is more. 

The State of Arizona just approved recreational cannabis in Arizona.  This is a potential windfall for Venom given the fact its brand, reputation and dispensary penetration from its award winning medical cannabis is about as good as it gets.  How good is Hollister now? 

How good does it get? 

Watch this incredible interview with Venom Extracts Founder Jake Cohen, the coolest exec in small cap cannabis because he delivers incredible results with sweat, swagger and great swag to boot.  

Watch this interview or listen by Podcast on AppleGoogleSpotify or your favourite podcaster.

Hollister $HOLL.ca $HSTRF Provides Comment on Approval of Recreational Cannabis in Arizona $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 10:58 PM on Wednesday, November 4th, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1
  • Company comments on the successful passage of Proposition 207 – legalizing the cultivation, sale and consumption of recreational cannabis in the state of Arizona
  • “Seeing recreational Cannabis legalized in the state is an encouraging sign and is hopefully another step toward federal legalization. It should lead to increased tax revenue and job creation. The recreational cannabis market in Arizona could be valued at up to US $760 million by 2024…” Shared Jacob Cohen , Founder of Venom Extracts, Hollister’s 100% owned subsidiary based in Arizona .

VANCOUVER, BC , Nov. 4, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the ” Company “, ” Hollister Cannabis Co. ” or ” Hollister “) a diversified cannabis branding company with products in over 280 dispensaries throughout California , and over 80 dispensaries throughout Arizona provides comment on the successful passage of Proposition 207 – legalizing the cultivation, sale and consumption of recreational cannabis in the state of Arizona .

“Seeing recreational Cannabis legalized in the state is an encouraging sign and is hopefully another step toward federal legalization. It should lead to increased tax revenue and job creation. The recreational cannabis market in Arizona could be valued at up to US $760 million by 2024 1 , significantly expanding the total addressable market for Cannabis in the state. We look forward to making our product line available to both the medical and recreational end user.” Shared Jacob Cohen , Founder of Venom Extracts, Hollister’s 100% owned subsidiary based in Arizona .

Arizona Presence

Hollister , through its 100% owned subsidiary, Venom Extracts (” Venom “), is one of Arizona’spremier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products. With an experienced management team and unparalleled reputation for quality, Venom prides itself as a differentiated extraction company by producing legal cannabis products at a price point that allows retailers to generate higher profits. Focused on proprietary efficiencies, Venom is able to produce more product per square foot than its competition, maintaining lower costs and risks than a typical extraction company.

Website: www.venomextracts.com

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CAbirthplace of the “American Biker”.

Website www.hollistercannabisco.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

 
Source:  Marijuana Business Daily

 View original content to download multimedia: http://www.prnewswire.com/news-releases/hollister-provides-comment-on-approval-of-recreational-cannabis-in-arizona-301166780.html

SOURCE Hollister Biosciences Inc.

How Cannabis-Based Therapeutics Could Help Fight #COVID Inflammation – SPONSOR: Innocan Pharma $INNO.ca $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 5:51 PM on Wednesday, November 4th, 2020
Innocan-Blog
  • InnoCan Pharma and Tel Aviv University are collaborating to explore the potential for CBD-loaded exosomes (minute extracellular particles that mediate intracellular communication, including via innate and adaptive immune responses)
  • The group plans to use these loaded exosomes to target and facilitate recovery of COVID-19–damaged lung cells
  • From a broader perspective, the prospects for harnessing cannabinoids for immune modulation will be more thoroughly explored in a special issue of Cannabis and Cannabinoid Research

By: Liz Scherer

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center.

Plagued by false starts, a few dashed hopes, but with perhaps a glimmer of light on the horizon, the race to find an effective treatment for COVID-19 continues. At last count, more than 300 treatments and 200 vaccines were in preclinical or clinical development (not to mention the numerous existing agents that are being evaluated for repurposing).

There is also a renewed interest in cannabinoid therapeutics — in particular, the nonpsychoactive agent cannabidiol (CBD) and the prospect of its modulating inflammatory and other disease-associated clinical indices, including SARS-CoV-2–induced viral load, hyperinflammation, the cytokine storm, and acute respiratory distress syndrome (ARDS).

Long hobbled by regulatory, political, and financial barriers, CBD’s potential ability to knock back COVID-19–related inflammation might just open doors that have been closed for years to CBD researchers.

Why CBD and Why Now?

CBD and the resulting therapeutics have been plagued by a complicated association with recreational cannabis use. It’s been just 2 years since CBD-based therapeutics moved into mainstream medicine — the US Food and Drug Administration (FDA) approved Epidiolex oral solution for the treatment of Lennox-Gastaut syndrome and Dravet syndrome, and in August, the FDA approved it for tuberous sclerosis complex.

CBD’s mechanism of action has not been fully elucidated, but on the basis of its role in immune responses — well described in research spanning more than two decades — it’s not surprising that cannabinoid researchers have thrown their hats into the COVID-19 drug development ring.

The anti-inflammatory potential of CBD is substantial and appears to be related to the fact that it shares 20 protein targets common to inflammation-related pathways, Jenny Wilkerson, PhD, research assistant professor at the University of Florida School of Pharmacy, Gainesville, Florida, explained to Medscape Medical News.

Among the various trials that are currently recruiting or are underway is one that is slated for completion this fall. CANDIDATE (Cannabidiol for COVID-19 Patients With Mild-to-Moderate COVID-19) is a randomized, controlled, double-blind study led by Brazilian researchers at the University of Sao Paulo. The study, which began recruitment this past August, enrolled 100 patients, 50 in the active treatment group (who received capsulated CBD 300 mg daily for 14 days plus pharmacologic therapy [antipyretics] and clinical measures) and 50 who received placebo.

Read Full Article: https://www.medscape.com/viewarticle/940265#vp_3

Arizona Voters Approve #Marijuana Legalization Ballot Measure SPONSOR: Hollister Biosciences $HOLL.ca $HSTRF $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 2:15 PM on Wednesday, November 4th, 2020

SPONSOR: Hollister Biosciences Inc. (HOLL:CSE) A vertically integrated Cannabis company with products in 280 California dispensaries, over 80 dispensaries throughout Arizona, joint ventures, licensing agreements and partnerships with Global brands. For the period beginning July 1 st , 2020 and ending September 30 th , 2020, Hollister generated record quarterly revenue of CDN$ 12.5 million and CDN$ 1.265 million in EBITDA. Learn More.

Arizona Voters Approve Marijuana Legalization Ballot Measure

  • A measure to legalize marijuana has been approved by Arizona voters, according to a projection by the Associated Press.
  • Advocates have paid close attention to the ballot initiative, as the state’s voters rejected a prior legal cannabis proposal in 2016.
  • Under the new legalization law, adults will be able to possess up to an ounce of marijuana at a time and cultivate up to six plants for personal use.

By Kyle Jaeger

AZ Proposition 207: Legalize Marijuana

CandidateVotesPercent
Yes done1,596,54859.85%
No1,071,25540.15%

2,667,803 votes counted. 81.64% – 98.11% in.

Results tracker sponsored by ETFMG | MJ.

“Until now, Arizona had imposed some of the strictest prohibition laws in the country; in some instances, the possession of even small amounts of marijuana was classified as a felony,” NORML Executive Director Erik Altieri said. “By rejecting this failed policy, no Arizonan going forward will be saddled with a criminal conviction for engaging in the personal possession or cultivation of cannabis, or face the lifelong stigma that comes with it.”

“Proposition 207 will disrupt the illicit market, end low-level marijuana arrests, create jobs and new revenue,” he added. “This result once again shows that marijuana legalization is not exclusively a ‘blue’ state issue, but an issue that is supported by a majority of all Americans—regardless of party politics.”

Polling was mixed heading into Election Day, with surveys consistently showing the proposal ahead, though by differing margins. In September, the Smart and Safe Arizona campaign shared an internal poll with Marijuana Moment that showed 57 percent of likely voters supported the  initiative, but a separate survey found just 46 percent in favor of the policy change. Additional polls last month showed the cannabis measure with a significant and growing lead.

The measure also contains several restorative justice provisions such as allowing individuals with prior marijuana convictions to petition the courts for expungements and establishing a social equity ownership program.

Cannabis sales will be taxed at 16 percent. Tax revenue will cover implementation costs and then be divided among funds for community colleges, infrastructure, a justice reinvestment and public services such as police and firefighters.

The Department of Health Services will be responsible for regulating the program and issuing cannabis business licenses. It will also be tasked with deciding on whether to expand the program to allow for delivery services.

The law technically goes into effect upon passage and after the voters are certified, which is expected to take place on November 30. After that point adults could legally use, possess and cultivate cannabis. However, regulators will still have to promulgate rules for overseeing the commercial industry. They can issue licenses starting in January 2021, and the first shops could be approved by February 1.

“Just four years after legalization was narrowly defeated, voters in Arizona turned out to send a clear message that they support marijuana legalization,” Steve Hawkins, executive director of the Marijuana Policy Project, said. “Following this victory, adults will no longer be treated as criminals for using a substance that is safer than alcohol and will be able to access it from safe and regulated businesses.”

Like other drug policy reform campaigns throughout the U.S., Smart and Safe Arizona faced significant obstacles qualifying its measure for the ballot amid the coronavirus pandemic.

At one point, activists asked the state Supreme Court to allow them to collect signatures electronically amid social distancing mandates, but that request was rejected.

Ultimately, the campaign submitted about 420,000 raw signatures. Secretary of State Katie Hobbs said that her office verified the petitions and determined that approximately 255,080 valid signatures were turned in. At least 237,645 were needed to qualify.

Opponents of the proposal, including Gov. Doug Ducey (R), released official voter guide arguments against the initiative in August. Supporters filed arguments as well, and all were circulated to voters in a pamphlet printed by the state.

Prohibitionists also released a series of attack ads that including misleading claims about what the measure would do and what has occurred in states that have already enacted cannabis legalization.

Source: https://www.marijuanamoment.net/arizona-voters-approve-marijuana-legalization-ballot-measure/

TransCanna $TCAN.ca Provides Corporate Update – Production Capacity of Lyfted Farms Facility is Currently Sold-Out Until March, 2021 $VFF.ca $ACB.ca $CGC.ca $GTII.ca $TEQ.ca

Posted by AGORACOM-JC at 10:22 AM on Monday, November 2nd, 2020
tcan-square
  • Final license achieved July 2020
  • 16,000 sq ft Distribution Space open for business in Q4
  • Contracts in place with much larger farms than the Company were able to service out of the smaller facility (16,000sq ft vs. 1,250 sq ft)
  • Build-out for cultivation has begun
  • The first harvest from cultivation in Daly expected in Q1
  • “Phase 1” Daly canopy sq. ft. capable of generating $30M + USD/year in cultivation revenue alone
  • In combination with increased Distribution capacity on track for 2021 rev target of $60M+ out of this facility

Vancouver, British Columbia–(November 2, 2020) – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) is very pleased to provide a corporate update:

  • Lyfted Farms Products are in High Demand and Selling Out
  • Lyfted Farms Secures Multiple Off-Take Agreements
  • Q4 Revenue Guidance
  • Crop Management Business Launched
  • Daly Facility Update

Product Update

Lyfted Farms flower is one of a very few branded indoor cultivation companies that routinely delivers on customer expectations for quality. This is reflected in the caliber of the retail stores that carry Lyfted Farms and by customer demand for our products. Lyfted Farms genetic library is fully capable of delivering new strains seasonally and has evolved into a trend-defining marketplace leader where other cannabis entities watch and emulate our products. Material process improvements have resulted in larger “nugget” sizing, increased THC levels, and a more robust curing cycle yielding better taste and aromatic profiles. These changes have had a positive effect on the pricing structure, with a 66% increase in wholesale pricing and a 100% increase in gross margins.

Off-Take Agreements

The Company has secured multiple off-take agreements in anticipation of late Q1 production coming out of the Daly facility. Shareholders will be given greater detail in subsequent news releases when all material details are finalized. As a result of the status of these agreements, the Company has tremendous confidence it will achieve or exceed its stated 2021 revenue targets.

Contracts with the likes of renowned retail partner Cookies, where Lyfted Farms currently has five sku’s in stores, provides the additional benefit of cost savings by not requiring a large in-house sales team or paying expensive 3rd party commissions, which are common in the Cannabis Sector.

Revenue Guidance

Lyfted Farms products produced out of the Company’s smaller Lyfted Farms facility continue to sell out and exceed sales expectations. Due to the increased capacity of the first 16,000 sq ft of distribution space in the Daly facility, the Company anticipates its Fourth Quarter to be its strongest of the year. The Company’s internal gross revenue target for the 2020 fiscal year ranges from CAD$12,000,000 up to CAD$14,000,000 (with anticipated net profits from sales of $600,000 up to $700,000). The Company is on track to achieve this benchmark.

With the opening of the Daly facility, associated off-take agreements, high demand for sales, and a strong distribution division, the Company maintains its guidance for a gross revenue target of CAD$55,000,000 to CAD$75,000,000 (with anticipated net profits from sales of $6,600,000 up to $9,000,000) for the fiscal year 2021. This revenue guidance is only for phase one of four in the Daly facility with phase one construction costs estimated to be CAD$3,172,500.

“With a significant portion of the year spent on submitting and obtaining licenses, we expect investor attention to shift to our 2021 performance. Our goal has always been to drive shareholder value through incremental sales contracts and quality products. This focus has us well-positioned to begin the build-out of the Daly building and scale our business,” States Bob Blink, company CEO. “I am very proud of how the team has come together through unprecedented events both globally and in our own back yard. 2021 will be a very exciting year for the Company.”

Crop Management Services Division

On October 8, 2020, the Company announced Lyfted Farms’ crop services management division (LFCSMD) first facility would come online January 1, 2021. This initiative is on schedule and will begin generating an additional revenue stream for the Company over and above the already thriving cultivation and distribution divisions. The first payments to LFCSMD are set to commence December 1, 2020. LFCSMD allows the Company to further monetize its genetic catalogue and further the Company’s reputation within the industry as best in class cultivators and operators. Additionally, this allows the Company to build out its supply chain — feeding its growing fulfillment and white-labeling business and maximizing efficiencies within the Daly Facility.

Daly Facility Update

The licensing and engineered build-out of the Daly Facility continues to be the core strength for the company. The amalgamation of a number of California’s strongest cannabis brands coming into the largest and most efficient facilities in the State is a truly powerful combination.

Updates at a glance:

  • Final license achieved July 2020
  • 16,000 sq ft Distribution Space open for business in Q4
    • contracts in place with much larger farms than the Company were able to service out of the smaller facility (16,000sq ft vs. 1,250 sq ft)
  • Build-out for cultivation has begun
  • The first harvest from cultivation in Daly expected in Q1
  • “Phase 1” Daly canopy sq. ft. capable of generating $30M + USD/year in cultivation revenue alone
  • In combination with increased Distribution capacity on track for 2021 rev target of $60M+ out of this facility

Other Highlights

Smaller Lyfted Farms Facility has outperformed expectations.

  • Production capacity of Lyfted Farms facility is currently sold-out until March, 2021
  • Average sales price per gram has increased from $5.70/gram to $8.57/gram, or +66% (increased demand and collaboration/co-branding) & 100% increase in gross margin
  • Average total harvest weight per room is trending up

Summary

Company performance and development of our team and human capital has been extraordinary. With the current global pandemic and wildfires in California, the Company has experienced many challenges over the past six months. The dedication and commitment by team members have given TransCanna stability and galvanized the opportunity for significant growth in the near term.

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a California based, Canadian listed Company building cannabis-focused brands for the California lifestyle through its wholly-owned California subsidiaries.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at [email protected].

On behalf of the Board of Directors
Bob Blink, CEO
604-349-3011

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs regarding future events of management of the Company. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. This information and these statements, referred to herein as “forward-looking statements”, are not historical facts, are made as of the date of this news release and include without limitation estimates and forecasts and statements as to management’s expectations for growth and the commencement of operations of the Company’s Daly facility.

The forward-looking information in this press release is based upon certain assumptions that management considers reasonable in the circumstances, including that operations will commence at the Company’s Daly facility in Modesto, California, as and when expected.

These forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially from any future results, events or developments expressed or implied by such forward-looking statements. Risks and uncertainties associated with the forward-looking information in this news release include, among others, dependence on obtaining and maintaining regulatory approvals, including state, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to complete upgrades to its Daly facility in a timely manner; engaging in activities which currently are illegal under U.S. federal law and the uncertainty of existing protection from U.S. federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including U.S. state-law legalization, particularly in California, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth;; reliance on management; and the effect of capital market conditions and other factors (including those related to the COVID-19 pandemic) on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look, except in accordance with applicable securities laws.

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN

CLIENT FEATURE: Avicanna $AVCN.ca $AVCNF Delivering The Vertically Integrated #Cannabis Company That Others Failed To $WEED.ca $TLRY $HARV.ca

Posted by AGORACOM-JC at 5:54 PM on Wednesday, October 28th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

Avicanna (AVCN :TSX) (AVCN : OTCQX) ( 0NN: FSE) is a vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global marketplace.

When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products as follows:

1.  The company has a full line of high end CBD based skin care products serving the consumer retail segment with Canadian distribution through Medical Cannabis by Shoppers, as well as global distribution later this year. 

2.  Avicanna’s superior medical cannabis line also features products distributed through Medical Cannabis by Shoppers, the online arm of Canada’s largest drugstore chain. In addition, the company recently received certification and authorization for the sale of pharmaceutical cannabinoid products with medical prescriptions in Colombia. 

3.  Avicanna also hosts a full pipeline of Pharmaceuticals in various stages of trials to address Dermatology, Psychiatry, Neurology, Pain and Oncology. Three of the company’s products are already as far as phase 2.

AND… if that is not enough …

4.  Avicanna’s Colombian cultivation division hosts 500,000 Sq ft of low cost and USDA certified organic Cannabis Cultivation. The company recently Made History As The First Ever Export Of Feminized Hemp Seeds From Colombia To The United States. 7,000,000 Seeds For $380,000, with an additional 75,000,000 Seeds Available For Export In Several Pending Transactions.

Hub On AGORACOM / Corporate Profile

Hollister Biosciences Inc. $HOLL.ca $HSTRF Provides Update on Q3 2020 Performance With Record Quarterly Revenue of CDN$ 12.5 million and CDN$ 1.265 million in EBITDA $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 8:18 AM on Tuesday, October 27th, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1
  • For the period beginning July 1st , 2020 and ending September 30th , 2020, Hollister reports that it generated record quarterly revenue of CDN$ 12.5 million and CDN$ 1.265 million in EBITDA from its product line of pre-rolls, concentrates, distillates, solvent-free bubble hash, pre-packaged flower, tinctures and vape products

VANCOUVER, BC , Oct. 27, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the ” Company “, ” Hollister Cannabis Co .” or ” Hollister “) a diversified cannabis branding company with products in over 280 dispensaries throughout California , and over 80 dispensaries throughout Arizona, is pleased to provide an update on its Q3, 2020 performance.

Q3 2020 Update

For the period beginning July 1 st , 2020 and ending September 30 th , 2020, Hollister reports that it generated record quarterly revenue of CDN$ 12.5 million and CDN$ 1.265 million in EBITDA from its product line of pre-rolls, concentrates, distillates, solvent-free bubble hash, pre-packaged flower, tinctures and vape products. The Company cautions that revenue and EBITDA figures have not yet been audited and are based on reports prepared by management.

“We are very pleased with our ability to deliver record quarterly revenue in such a challenging market environment. We attribute our revenue growth to further penetration of the California and Arizona dispensary networks and successful new product launches with our joint venture partners.  We hope to continue this positive momentum into year-end” stated Carl Saling , CEO.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

Avicanna $AVCN.ca Announces Results of Annual General and Special Meeting $WEED.ca $CL.ca $HEXO.ca

Posted by AGORACOM-JC at 6:56 PM on Tuesday, October 20th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

  • Announced that all of management’s nominees listed in the Company’s management information circular dated September 22, 2020 were elected as directors of the Company at Avicanna’s annual general and special meeting of shareholders held on October 20, 2020.

TORONTO , Oct. 20, 2020 – Avicanna Inc. (” Avicanna ” or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of cannabinoid-based products, is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated September 22, 2020 were elected as directors of the Company at Avicanna’s annual general and special meeting of shareholders held on October 20, 2020 (the ” Meeting “). The detailed results of the vote for the election of directors held at the Meeting are set out below.

Name of NomineeVotes cast FOR% votes cast
FOR
Votes
WITHHELD
% votes
WITHHELD
Aras Azadian11,304,32199.94%7,3500.06%
Setu Purohit11,304,32199.94%7,3500.06%
Giancarlo Davila Char11,304,21599.93%7,4560.07%
Dr. Chandrakant Panchal11,304,32199.94%7,3500.06%
David Allan White11,304,72199.94%6,9500.06%
Janet Giesselman11,304,72199.94%6,9500.06%
Benjamin Leavenworth11,304,41599.94%7,2560.06%

At the Meeting, the Company’s shareholders also approved the appointment of MNP LLP as the Company’s auditors for the ensuing year, authorized the board of directors to fix the auditors’ remuneration and approved cancellation and re-issuance of certain stock options previously granted to, among others, certain insiders of the Company.

About Avicanna

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.

Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:

  • Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and,
  • RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.

With ongoing clinical trials on its derma-cosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.

Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020, Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia.

Stay Connected

For more information about Avicanna, visit www.avicanna.com , call 1-647-243-5283, or contact Setu Purohit , President by email [email protected] .

Shifting Trends #CBD and The “Big Pharma” – SPONSOR: Avicanna $AVCN.ca $AVCNF $GWPH $PCLO.ca $CRBP

Posted by AGORACOM-JC at 3:34 PM on Monday, October 19th, 2020

SPONSOR: Avicanna (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is a Canadian vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global market place. When we say vertically integrated, we mean it.  Avicanna has 4 fully operating divisions to address the entire market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when Avicanna offers you exposure to the entire vertical. Learn More.

http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

Shifting Trends – CBD and The “Big Pharma”

  • According to a study, more than 42% of the people who use hemp-derived products and CBD have stooped using synthetic drugs and pharmaceuticals to tackle their medical conditions effectively
  • What this figure shows is a shift of consumers’ confidence towards these natural products rather than the synthetic ones

By: Jamie Moses

With the increasingly immense popularity of CBD and other hemp-based products, the role of naturally extracted medicine in the realm of the global medicinal industry and big pharmaceuticals is growing at a rapid rate. As various studies and researches have proven the beneficial medical impacts of these CBD compounds, their use for the purposes of health and wellbeing is becoming more and more popular. 

The battle between naturally extracted medicine and pharmaceuticals has always been a controversial debate. The role of big pharma” in health and the theories revolving around their shady impacts has always been contentious. Especially after the wide range popularity and cultivation of CBD and its products such as CBD oils, this issue has been highlighted even more. While the big pharma relies on chemicals and synthetics processes for their medicine to interact and work on the human body, natural medicine is more palatable and relies on its structure and nature to be able to bind with the targetted receptors of the body to provide satisfactory results. 

According to a study, more than 42% of the people who use hemp-derived products and CBD have stooped using synthetic drugs and pharmaceuticals to tackle their medical conditions effectively. What this figure shows is a shift of consumers’ confidence towards these natural products rather than the synthetic ones. But why is this change of dynamics occurring so suddenly after the discovery of CBD, when the use of herbal medicine is not at all a new trend and dates back many years? According to WHO, more than half of the world population already uses herbal means for their medical anomalies then why is the impact created by CBD so immense? The answer lies in its qualities and various medical benefits it imparts on the body with little or no side effects. The reasons why people are turning towards CBD oils and plant medicine are provided here.

High costs – Both financial and physical:

Pharmaceutical options may be more effective in terms of their selective activism and rapid action by IV fluids, but they come with a high price. Medical insurances and various critical condition drugs are almost too expensive for every citizen to get. This has created a trend among people to shift towards natural means of medicine and wellbeing and that is where CBD oil has been so much dominant. The lower production overheads and a non-monopolized market have kept the prices of these drugs quite lower as compared to the pharmaceuticals. 

Effectiveness:

According to a study, 52% of the people using CBD products daily or regular;y have reported these drugs to be more effective than the pharmaceuticals. The extended researches done have shown that the first-hand reactions of those people are in fact accurate and CBD really works better for them. It has to do with the fact that CBD oil can activate the ECS system of the body and can antagonize the CB1 and Cb2 receptors binding with them effects to provide good results. Moreover, the non-psychoactive nature of CBD means it does not get you “high: or mind-altered like other cannabis-derivatives THC.

Multi-purpose:

Various studies have shown that CBD is a medical marvel that can be used to treat various medical conditions. People are now using CBD Oil for pain, anxiety, depression, stress, insomnia, neurogenesis, anti-cancer treatments, skin condition, and even heart problems. With the recent researches proving the effectiveness of CBD in these medical anomalies and a wide range of consumption options available to the people, it is no shock that CBD products are upholding the drug market right now.

Side-effects:

According to a study conducted over a span of 30 years gathering information from various hospitals, almost 7% of the people using big pharma drugs are likely to have serious reactions to the medicines and require immediate medical attention. Many more have mild to low side effects after using these pharmaceuticals. This has also caused the people to start using alternatives and look for safer and natural options. 

Final thoughts:

Although the medical effectiveness and easy access is a major factor in the favor of cannabis products, the lingering confusion regarding its legal status and dosage regulations still cause hurdles in the way. With the recent law changes, the hemp cultivation has seen an uprise and only by educating people more can this industry of herbal medicine become more effective and provide for the betterment of mankind. 

Source: https://artvoice.com/2020/08/17/shifting-trends-cbd-and-the-big-pharma/

#CBD Skin Care Market Is Booming Worldwide with Strong Growth – Avicanna $AVCN.ca $AVCNF $WEED.ca $CL.ca $HEXO.ca

Posted by AGORACOM-JC at 2:44 PM on Wednesday, October 14th, 2020

SPONSOR: Avicanna (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is a Canadian vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global market place. When we say vertically integrated, we mean it.  Avicanna has 4 fully operating divisions to address the entire market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when Avicanna offers you exposure to the entire vertical. Learn More.

http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

CBD Skin Care Market Is Booming Worldwide with Strong Growth

Multi-functional attributes such as powerful antioxidants and anti-inflammatory properties of Cannabidiol (CBD) driving the demand for CBD skincare products. It is useful in the treatment of eczema, psoriasis, and acne. The market has high growth prospects owing to rising awareness about skin healing properties of CBD and growing preference for sustainable skincare products. Moreover, the growing online distribution channels for CBD skincare products expected to drive the product demand during the forecasted period.This growth is primarily driven by Rising Awareness about Skin Healing Properties of CBD and Growing Preference for Sustainable Skin Care Products.

AMA Research have added latest edition of survey study on CBD Skin Care Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. The research study provides estimates for CBD Skin Care  Forecast till 2025*.

Important Features that are under offering & key highlights of the report:

1) How Study Have Considered the Impact of COVID-19 / Economic Slowdown of 2020 ?

Analyst at AMA are constantly gathering and conducting survey with opinion leaders and Industry experts from various region to minutely understand impact on growth as well as local reforms to evaluate study and market estimates. Due to lockdown different online medium and procedures are followed like Survey Monkey, LinkedIn Connections, and Email reach and industry forum to established industry viewpoint to garner rich insights for study. A special chapter in the study presents Impact Analysis of COVID-19 on CBD Skin Care  Market along with tables and graphs related to various country and segments showcasing impact on growth trends.

2) Can list of players be customize according to targeted regional geographies to match business objective?

Considering heat map analysis and based on market buzz or voice the profiled list of companies in the report are ” Kiehl’s LLC (United States), Cannuka LLC (United States), Elixinol Global Limited (Australia), Medical Marijuana Inc. (United States), Endoca LL (Netherland), Lord Jones (United States), Kapu Maku LLC (United States), Leef Organics (United States), FAB CBD (United States), IRIE CBD (United States) and Kazmira (United States)”. Yes, further list of players can also be customized as per your requirement keeping in mind your areas of interest and adding local emerging players and leaders from targeted geography. 

3) Can Market be broken down by different set of application and types?

Additional segmentation / Market breakdown is possible subject to data availability, feasibility and depending upon timeline and toughness of survey. However a detailed requirement needs to be prepared before making any final confirmation. 

** 3+ Additional country of your interest can be included at no added cost feasibility test would be conducted by Analyst team of AMA based on the requirement shared and accordingly deliverable time will also be disclosed. 

Market Drivers

  • Rising Awareness about Skin Healing Properties of CBD
  • Growing Preference for Sustainable Skin Care Products

Market Trend

  • Growing Acceptance of CBD Products

Restraints

  • Stringent Government Regulations Regarding CBD Product Manufacturing

CBD Skin Care

by Type (Oil, Serums, Moisturizers & Cream, Cleansers, Sunscreens, Others (Lip Balm, Mask Etc.)), Application (Dry Skin, Psoriasis, Eczema, Acne), Distribution Channel (Departmental Stores, E-Commerce, Hypermarkets/Supermarkets, Retail Pharmacies, Others), Source (Hemp, Marijuana) 

Read More: https://eurowire.co/uncategorized/167129/cbd-skin-care-market-is-booming-worldwide-with-strong-growth-lord-jones-leef-organics-kazmira/